Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 245,923 shares were traded during trading, a decline of 19% from the previous session’s volume of 304,867 shares.The stock last traded at $7.6750 and had previously closed at $8.03.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
Read Our Latest Analysis on RGC
Regencell Bioscience Stock Performance
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.
Institutional Trading of Regencell Bioscience
Several institutional investors and hedge funds have recently made changes to their positions in RGC. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the second quarter worth about $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the 2nd quarter worth about $768,000. XTX Topco Ltd purchased a new position in Regencell Bioscience during the 3rd quarter valued at about $598,000. Vident Advisory LLC increased its position in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Read More
- Five stocks we like better than Regencell Bioscience
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
- General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
